Immunological therapy: A novel thriving area for triple-negative breast cancer treatment. (1st February 2019)

• Record Type: Journal Article
• Authors: Wang, Xiangyu; Qi, Yihang; Kong, Xiangyi; Zhai, Jie; Li, Yalun; Song, Yan; Wang, Jing; Feng, Xiaoli; Fang, Yi
• Is Part Of: Cancer letters. Volume 442(2019)
• Page Start: 409
• Page End: 428
• Publication Date: 2019-02-01
• Subjects: Triple-negative breast cancer -- Immunotherapy -- Research progress; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2018.10.042
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Triple-negative breast cancer (TNBC) refers to cancers that are low in expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). TNBC tends to behave more aggressively than other types of breast cancer. Unlike other breast cancer subtypes (ie, ER-positive, HER2-positive subtypes), there are no approved targeted treatments available, other than the administration of chemotherapy. Immunotherapy is a new kind of treatment approach for TNBC when compared with the surgical treatment, chemotherapy, endocrine therapy, and molecular targeting therapy. The present article reviews the research progresses of immunotherapy for TNBC in recent years. The full text structure covers molecular classification of TNBC, active immunotherapy of TNBC, passive immunotherapy of TNBC, oncolytic immunotherapy and the prospect of immunotherapy for TNBC. Highlights: Accounting about 15% of breast cancer, TNBC is the pathologic type leading to the highest mortality and worst prognosis. Immunotherapy is another important treatment approach following surgical treatment and other adjuvant therapies. Active immunotherapy includes immune checkpoint blocking, vaccines, cancer-testis antigen and cancers relevant target immunotherapy. Passive immunotherapy of TNBC consists of CART treatment and CIK treatment. Oncolytic Immunotherapy mainly refers to chimeric parapoxvirus CF189.